Flovent (Asthma) - Forecast and Market Analysis to 2023, New Report Launched

The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has also been facing increasing generic competition. However, the launch of seven novel targeted biologic agents and once-daily ICS and ICS/LABA therapies delivered by the next-generation inhalers will strongly drive the market growth over the next 10 years. The biologic agents will not only reshape the market growth, but will also mark the beginning of a new era of a personalized approach to asthma treatment. The realization that asthma is a very heterogeneous disease is highly reflected in the rich assortment of these targeted therapies in the late-stage pipeline.

Originally approved by the Food and Drug Administration (FDA) in 1996, GSK’s Flovent (fluticasone propionate) is a synthetic ICS therapy with potent anti-inflammatory activity. It is used for the maintenance treatment of asthma prophylactically in children and adults. Flovent is now available in two formulations, Diskus and HFA, which received the FDA approval in 2000 and 2004, respectively. Flovent’s active ingredient, fluticasone propionate, can bind to glucocorticoid receptors with high affinity and inhibit the secretion of mediators involved in asthma, such as histamine, eicosanoids, leukotrienes, and cytokines. It is three times more potent than budenoside, and two times more potent than the active metabolite of beclomethasone dipropionate.

Scope

• Overview of Asthma, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
• Detailed information on Flovent including product description, safety and efficacy profiles as well as a SWOT analysis.
• Sales forecast for Flovent for the top eight countries from 2013 to 2023.
• Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia.

Reasons to buy

• Understand and capitalize by identifying products that are most likely to ensure a robust return
• Stay ahead of the competition by understanding the changing competitive landscape for Asthma
• Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
• Make more informed business decisions from insightful and in-depth analysis of Flovent performance
• Obtain sales forecast for Flovent from 2013-2023 in top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and Australia)

Spanning over 52 pages, “Flovent (Asthma) - Forecast and Market Analysis to 2023” report covering the Introduction, Disease Overview, Disease Management, Competitive Assessment, Flovent (fluticasone propionate), Appendix.

Know more about this report at – http://mrr.cm/ZzP

Related Reports:

1st - Pulmicort (Asthma) - Forecast and Market Analysis to 2023 - visit at: http://mrr.cm/ZzW

2nd - Singulair (Asthma) - Forecast and Market Analysis to 2023 - visit at: http://mrr.cm/Zzm

3rd - Advair (Asthma) - Forecast and Market Analysis to 2023 - visit at: http://mrr.cm/Zzs